Alembic Pharmaceuticals Wins US FDA Approval for Generic Efinaconazole Topical Solution
Alembic Pharmaceuticals receives US FDA approval for generic efinaconazole topical solution, targeting a US market estimated at USD 500 million.
Jublia Topical Solution | 24/02/2026 | By News Bureau | 170
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy